All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
GSK secures FDA approval for Nucala to treat COPD in adults
Nucala is a monoclonal antibody that targets interleukin-5 (IL-5), a cytokine involved in type 2 inflammation and is already approved in Europe and the US for IL-5-mediated conditions
Aptar Digital Health, AstraZeneca partner for AI screening algorithms
The collaboration aims to leverage AstraZeneca’s AI-driven screening algorithms, developed based on thousands of biomarkers and diagnosis data points, to advance CKD detection during eye examinations
Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions
The collaboration between Twist and Element will enable researchers to access end-to-end workflows from library prep through sequencing on Element’s AVITI platform
Sanofi to acquire Vigil for $470m to enhance neurology pipeline
The acquisition will strengthen Sanofi’s early-stage pipeline with the addition of VG-3927, an investigational treatment for Alzheimer’s disease, set to enter a Phase 2 clinical study.
Orionis partners with Genentech for cancer drug development
Orionis will lead the discovery and optimisation of molecular glues, while Genentech will manage the later stages of preclinical and clinical development, regulatory filing, and commercialisation
Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies
The transaction was financed with capital from Paratek, B-FLEXION Life Sciences, and Novo Holdings, and debt financing from funds managed by Oaktree Capital Management, L.P. (“Oaktree”).
Pfizer secures global rights for 3SBio’s SSGJ-707 outside China
SSGJ-707 is a bispecific antibody that targets PD-1 and VEGF, currently studied in China, for non-small cell lung cancer, metastatic colorectal cancer, and gynaecological tumours.
SIFI secures UK’s MHRA marketing authorisation for Akantior
The MHRA authorisation fulfils the Italian ophthalmic company’s efforts in developing polihexanide as an active pharmaceutical ingredient, adhering to good manufacturing practices
BioMarin to acquire Inozyme to enhance its enzyme therapy portfolio
The acquisition, which has been approved by both companies’ boards, is expected to be completed in the third quarter of 2025, subject to regulatory approval and certain customary closing conditions
BMS secures EC approval for Opdivo regimen to treat NSCLC with PD-L1
The EC approval is based on the CheckMate -77T study, which compared the Opdivo regimen with a neoadjuvant platinum-doublet chemotherapy and placebo.